Dynavax Technologies Corp. (DVAX) Commences Phase 1b Clinical Trial of Universal Flu Vaccine in Collaboration with Novartis
Dynavax Technologies Corp., a clinical-stage biopharmaceutical company, today announced it has begun to immunize patients in a phase 1b clinical trial of its universal flu vaccine candidate N8295, to evaluate the safety the drug when combined with Novartis’ investigational H5N1 avian influenza vaccine. Dynavax’s first step in the ongoing development of N8295 was establishing the safety of the candidate through preliminary phase 1a testing of the candidate standing alone, in which no dose limiting toxicities were identified. This has allowed the company to launch the phase 1b study six months ahead of schedule. The next step is to test the…